Aptahem AB (publ)

Climate Impact & Sustainability Data (2020-2022, 2023-01-01 to 2023-12-31)

Medium-term Goals:

Short-term Goals:

Risks related to preclinical and clinical studies (high probability, high negative impact)
Risks related to recruitment of test subjects or patients (medium probability, medium negative impact)
Risks related to the failure to launch and/or the failure to sell/license a drug candidate (medium probability, high negative impact)
Risks related to dependence on key personnel and qualified employees (medium probability, medium negative impact)
Risks related to suppliers, manufacturers and partners (low probability, medium negative impact)
Risks related to side effects (low probability, high negative impact)
Risks related to future capital needs (medium probability, high negative impact)
Risks related to patents and other intangible assets (medium probability, high negative impact)
Risks related to relevant permits and approvals (low probability, high negative impact)
Risks related to future new issues and dilution
Risks related to share price development, volatility and liquidity
Risks related to macroeconomic factors' impact on the rights issue
Subscription commitments not secured

The company is seeking to raise capital through a rights issue to fund its development projects and operations.
The company is actively seeking partnerships or licensing agreements to further fund development and clinical trials.

The war in Ukraine and Israel could impact all operations. The company's operations are mainly in Sweden, so the impact has been limited up to the signing of the annual report. No projects or activities have been canceled at the time of signing. Market uncertainty exists due to the ongoing conflicts, potentially affecting costs and timelines.